Terms: = Breast cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
749 results:
1. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract] [Full Text] [Related]
2. The β2-adrenergic receptor associates with cxcr4 multimers in human cancer cells.
Liang J; Seghiri M; Singh PK; Seo HG; Lee JY; Jo Y; Song YB; Park C; Zalicki P; Jeong JY; Huh WK; Caculitan NG; Smith AW
Proc Natl Acad Sci U S A; 2024 Apr; 121(14):e2304897121. PubMed ID: 38547061
[TBL] [Abstract] [Full Text] [Related]
3. cxcr4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced cancer Therapy through Codelivery of Manganese and Doxorubicin.
Jang Y; Cho YS; Kim A; Zhou X; Kim Y; Wan Z; Moon JJ; Park H
ACS Appl Mater Interfaces; 2024 Apr; 16(14):17129-17144. PubMed ID: 38533538
[TBL] [Abstract] [Full Text] [Related]
4. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.
Moradi Z; Kazemi M; Jamshidi-Khalifelou R; Bahramnia V; Esfandmaz F; Rahnavard R; Moradgholi B; Piri-Gharaghie T
Funct Integr Genomics; 2024 Mar; 24(2):61. PubMed ID: 38507114
[TBL] [Abstract] [Full Text] [Related]
5. Synergy between PEDF and Doxorubicin in breast cancer Cells: Effects on Metastatic and Metabolic Pathways.
Abooshahab R; Al-Salami H; Dass CR
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474001
[TBL] [Abstract] [Full Text] [Related]
6. Anti-collagenase, Anti-elastase, Anti-urease, and Anti-cancer Potentials of Isokaempferide as Natural Compound: In vitro and in silico Study.
Yin Q; Zhang H; Huang T; Liu B; Negm S; El-Kott AF
J Oleo Sci; 2024; 73(2):187-199. PubMed ID: 38311409
[TBL] [Abstract] [Full Text] [Related]
7. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of immune density, PD-L1, and cxcr4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
[TBL] [Abstract] [Full Text] [Related]
9. Unlocking the Power of the Homing Phenomenon: Why breast Conserving Surgery Outshines Mastectomy in Overall Survival.
Mokbel K
Clin Breast Cancer; 2024 Feb; 24(2):85-92. PubMed ID: 37925361
[TBL] [Abstract] [Full Text] [Related]
10. LPA1-mediated inhibition of cxcr4 attenuates CXCL12-induced signaling and cell migration.
Hong JM; Lee JW; Seen DS; Jeong JY; Huh WK
Cell Commun Signal; 2023 Sep; 21(1):257. PubMed ID: 37749552
[TBL] [Abstract] [Full Text] [Related]
11. Tamoxifen as a modulator of CXCL12-cxcr4-CXCR7 chemokine axis: A breast cancer and glioblastoma view.
Gonçalves TL; de Araújo LP; Pereira Ferrer V
Cytokine; 2023 Oct; 170():156344. PubMed ID: 37639844
[TBL] [Abstract] [Full Text] [Related]
12. Research Progress of cxcr4-Targeting Radioligands for Oncologic Imaging.
Wang Y; Gao F
Korean J Radiol; 2023 Sep; 24(9):871-889. PubMed ID: 37634642
[TBL] [Abstract] [Full Text] [Related]
13. Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells.
Sharifhoseini A; Heshmati M; Soltani A; Entezam M; Shirzad H; Sedehi M; Judd BA; Jami MS; Ghatrehsamani M
Mol Biol Rep; 2023 Oct; 50(10):8319-8328. PubMed ID: 37589934
[TBL] [Abstract] [Full Text] [Related]
14. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract] [Full Text] [Related]
15. Development of a Rare Earth Nanoprobe Enables In Vivo Real-Time Detection of Sentinel Lymph Node Metastasis of breast cancer Using NIR-IIb Imaging.
Zhu YY; Song L; Zhang YQ; Liu WL; Chen WL; Gao WL; Zhang LX; Wang JZ; Ming ZH; Zhang Y; Zhang GJ
Cancer Res; 2023 Oct; 83(20):3428-3441. PubMed ID: 37540231
[TBL] [Abstract] [Full Text] [Related]
16. CXCL12-cxcr4/CXCR7 Axis in cancer: from Mechanisms to Clinical Applications.
Yang Y; Li J; Lei W; Wang H; Ni Y; Liu Y; Yan H; Tian Y; Wang Z; Yang Z; Yang S; Yang Y; Wang Q
Int J Biol Sci; 2023; 19(11):3341-3359. PubMed ID: 37497001
[TBL] [Abstract] [Full Text] [Related]
17. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of cxcr4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract] [Full Text] [Related]
18. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
19. cxcr4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.
Yu J; Zhou X; Shen L
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375261
[TBL] [Abstract] [Full Text] [Related]
20. Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor.
Sawant M; Wilson A; Sridaran D; Mahajan K; O'Conor CJ; Hagemann IS; Luo J; Weimholt C; Li T; Roa JC; Pandey A; Wu X; Mahajan NP
Oncogene; 2023 Jul; 42(29):2263-2277. PubMed ID: 37330596
[TBL] [Abstract] [Full Text] [Related]
[Next]
